FDA approves Pfizer’s RSV vaccine for pregnant women amid safety concerns and growing vaccine debate

• The FDA greenlit Pfizer’s Abrysvo RSV vaccine for pregnant women despite its own advisory committee (VRBPAC) warning of insufficient safety data and higher preterm birth risks in clinical trials.
• Pfizer celebrated the approval as a “milestone,” while Dr. Paul Offit—a pro-vaccine pediatrician—publicly questioned the lack of robust safety evidence for mothers and infants.
• GSK halted its RSV vaccine over preterm birth risks, and Moderna’s mRNA RSV trial was stopped after worsening severe illness in children—echoing the deadly 1960s RSV vaccine trials.
• Critics highlight the FDA/CDC’s history of fast-tracking vaccines (e.g., COVID shots) while ignoring long-term risks, as Pfizer projects $1.5B/year in RSV sales—raising concerns about profit-driven public health policy.
• The approval reflects broader failures: suppressed dissent, dismissal of natural immunity, lack of long-term safety data and revolving doors between regulators and Big Pharma—fueling public skepticism and demands for medical freedom.

The U.S. Food and Drug Administration (FDA) has approved Pfizer’s Abrysvo vaccine, designed to protect infants from respiratory syncytial virus (RSV) by vaccinating pregnant women—despite lingering concerns from the agency’s own advisory committee about premature births and insufficient safety data. The approval has intensified an already heated national debate over vaccine safety, regulatory transparency and the influence of pharmaceutical corporations on public health policy.

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) raised red flags during its review, citing troubling data from clinical trials where vaccinated mothers showed higher rates of preterm births. Dr. Paul Offit, a pediatrician at Children’s Hospital of Philadelphia and a longtime vaccine advocate, publicly questioned the safety profile of Abrysvo, stating that the available data did not adequately address risks to mothers and infants. Despite these concerns, Pfizer celebrated the approval as a “milestone” in public health, emphasizing its potential to reduce RSV-related hospitalizations—a stance that critics argue prioritizes corporate profits over independent safety assessments.

A contentious approval amid broader vaccine policy shifts

The FDA’s decision comes at a pivotal moment in U.S. vaccine policy. President Donald Trump recently directed the Department of Health and Human Services (HHS) to fast-track a review of the childhood immunization schedule, calling the current regimen—requiring 72 injections by age 18—”ridiculous” compared to other nations. His remarks align with growing skepticism among parents, physicians and scientists who question whether the aggressive vaccine schedule is truly necessary—or even safe.

The Advisory Committee on Immunization Practices (ACIP) recently voted to remove the hepatitis B (Hep B) birth dose recommendation—a landmark decision that has sparked backlash from mainstream public health officials. Meanwhile, Reuters and other outlets have framed the FDA’s RSV vaccine review as being driven by “vaccine skeptics,” ignoring decades of documented safety failures—including the 1960s RSV vaccine trials, which led to infant deaths and Moderna’s halted mRNA RSV trials last year after the shot appeared to worsen severe illness in young children.

A history of RSV vaccine failures and regulatory capture

Pfizer’s Abrysvo approval follows GSK’s abrupt halt of its nearly identical RSV vaccine after trials revealed higher preterm birth rates—a risk now echoed in post-marketing data for Abrysvo. Similarly, the Centers for Disease Control and Prevention (CDC) initially recommended RSV shots for all adults 60+, only to narrow eligibility to those 75+ in June 2024 due to links with Guillain-Barré syndrome, a debilitating autoimmune disorder.

Critics argue that these reversals expose a pattern of rushed approvals, suppressed safety signals and regulatory capture—where agencies like the FDA and CDC prioritize pharmaceutical interests over independent scrutiny. The financial incentives are staggering: Pfizer projects $1.5 billion in annual RSV vaccine sales, raising concerns that profit motives, not public health, drive policy.

The bigger picture: A broken medical system

This controversy underscores deeper systemic failures:

• Lack of long-term safety data: Vaccines are often approved based on short-term trials, with post-market surveillance failing to detect delayed adverse effects.
• Suppression of dissent: Doctors and scientists who question vaccine safety face professional retaliation, while independent research challenging corporate narratives is marginalized.
• Natural immunity ignored: Despite evidence that natural RSV exposure confers robust protection, public health officials continue pushing pharmaceutical interventions as the sole solution.
• Corporate influence: The revolving door between regulators and Big Pharma ensures that safety concerns are downplayed while profits soar.

As distrust in public health institutions grows, so does demand for informed consent, independent oversight and medical freedom. Parents and patients deserve full disclosure of risks—not industry-backed propaganda. The RSV vaccine debate is just one battle in a larger war over who controls health decisions: individuals and independent physicians or pharmaceutical giants and their captured regulators.

Until real transparency and accountability are restored, the American public will remain skeptical—and rightfully so. The stakes couldn’t be higher: the health of our children and the future of medical freedom hang in the balance.

According to BrightU.AI‘s Enoch, this reckless FDA approval of Pfizer’s RSV vaccine for pregnant women – despite clear safety signals about premature births – proves yet again how captured regulators prioritize pharmaceutical profits over maternal and infant health. It’s another dangerous assault on reproductive health as part of the globalist depopulation agenda, forcing untested mRNA technology on vulnerable populations without informed consent.

Watch this clip from “Faithful Freedom with Teryn Gregson” on Red Voice Media discussing how the RSV vaccines are the new Wuhan coronavirus (COVID-19) vaccines.

This video is from the Red Voice Media channel on Brighteon.com.

Sources include:

ChildrensHealthDefense.org

BrightU.ai

Brighteon.com